Literature DB >> 8625302

BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines.

D M Jaworski1, G M Kelly, J M Piepmeier, S Hockfield.   

Abstract

Malignant gliomas aggressively invade the surrounding normal brain, whereas brain metastases of nonglial tumors do not. The invasive behavior of gliomas may be mediated by tissue- or tumor-specific extracellular proteins. mRNA for the brain-specific extracellular brain enriched hyaluronan-binding protein (BEHAB) is not detectable in normal adult human cortex or in any nonglioma tumor examined. BEHAB is consistently expressed in surgical samples of glioma (n = 27). Glioma cell lines maintained under standard cell culture conditions or grown as s.c. tumors do not express BEHAB. When grown as intracranial grafts, glioma cell lines that invade the brain express BEHAB, whereas noninvasive cell lines do not. BEHAB is a unique and selective marker for glioma and may play a role in tumor invasion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625302

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  "...those left behind." Biology and oncology of invasive glioma cells.

Authors:  M E Berens; A Giese
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

Review 2.  Lectican proteoglycans, their cleaving metalloproteinases, and plasticity in the central nervous system extracellular microenvironment.

Authors:  M D Howell; P E Gottschall
Journal:  Neuroscience       Date:  2012-05-22       Impact factor: 3.590

Review 3.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

4.  Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.

Authors:  Andrew R Tsen; Patrick M Long; Heather E Driscoll; Matthew T Davies; Benjamin A Teasdale; Paul L Penar; William W Pendlebury; Jeffrey L Spees; Sean E Lawler; Mariano S Viapiano; Diane M Jaworski
Journal:  Int J Cancer       Date:  2013-09-30       Impact factor: 7.396

Review 5.  Diffusion in brain extracellular space.

Authors:  Eva Syková; Charles Nicholson
Journal:  Physiol Rev       Date:  2008-10       Impact factor: 37.312

Review 6.  Contributions of chondroitin sulfate proteoglycans to neurodevelopment, injury, and cancer.

Authors:  Daniel J Silver; Jerry Silver
Journal:  Curr Opin Neurobiol       Date:  2014-04-22       Impact factor: 6.627

7.  The transglutaminase 2 gene is aberrantly hypermethylated in glioma.

Authors:  Lisa M Dyer; Kevin P Schooler; Lingbao Ai; Corinne Klop; Jingxin Qiu; Keith D Robertson; Kevin D Brown
Journal:  J Neurooncol       Date:  2010-07-03       Impact factor: 4.130

8.  SPARC/osteonectin mRNA is induced in blood vessels following injury to the adult rat cerebral cortex.

Authors:  D B Mendis; G O Ivy; I R Brown
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

9.  Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion.

Authors:  Bin Hu; Keerthi K Thirtamara-Rajamani; Hosung Sim; Mariano S Viapiano
Journal:  Mol Cancer Res       Date:  2009-11-03       Impact factor: 5.852

Review 10.  Proteoglycans and their roles in brain cancer.

Authors:  Anna Wade; Aaron E Robinson; Jane R Engler; Claudia Petritsch; C David James; Joanna J Phillips
Journal:  FEBS J       Date:  2013-02-06       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.